- Home
- NUVL vs LEGN Comparison
NUVL vs LEGN Comparison
Compare NUVL & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- LEGN
- Stock Information
- Founded
- NUVL 2017
- LEGN 2014
- Country
- NUVL United States
- LEGN United States
- Employees
- NUVL N/A
- LEGN N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- NUVL Health Care
- LEGN Health Care
- Exchange
- NUVL Nasdaq
- LEGN Nasdaq
- Market Cap
- NUVL 5.8B
- LEGN 6.7B
- IPO Year
- NUVL 2021
- LEGN 2020
- Fundamental
- Price
- NUVL $78.64
- LEGN $34.47
- Analyst Decision
- NUVL Strong Buy
- LEGN Strong Buy
- Analyst Count
- NUVL 11
- LEGN 12
- Target Price
- NUVL $120.91
- LEGN $73.36
- AVG Volume (30 Days)
- NUVL 390.3K
- LEGN 1.1M
- Earning Date
- NUVL 11-11-2025
- LEGN 11-11-2025
- Dividend Yield
- NUVL N/A
- LEGN N/A
- EPS Growth
- NUVL N/A
- LEGN N/A
- EPS
- NUVL N/A
- LEGN N/A
- Revenue
- NUVL N/A
- LEGN $796,838,000.00
- Revenue This Year
- NUVL N/A
- LEGN $70.75
- Revenue Next Year
- NUVL N/A
- LEGN $52.47
- P/E Ratio
- NUVL N/A
- LEGN N/A
- Revenue Growth
- NUVL N/A
- LEGN 74.75
- 52 Week Low
- NUVL $55.54
- LEGN $27.34
- 52 Week High
- NUVL $110.00
- LEGN $52.15
- Technical
- Relative Strength Index (RSI)
- NUVL 51.21
- LEGN 44.92
- Support Level
- NUVL $77.88
- LEGN $32.70
- Resistance Level
- NUVL $83.09
- LEGN $34.71
- Average True Range (ATR)
- NUVL 3.14
- LEGN 1.21
- MACD
- NUVL 0.14
- LEGN 0.07
- Stochastic Oscillator
- NUVL 48.79
- LEGN 46.90
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.